#United States #Boston #TTX-MC138 #metastatic cancer #TransCode Therap

TransCode Therapeutics Advances in Cancer Treatment

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a company focused on pioneering immuno-oncology and RNA therapies for cancer treatment, has made significant progress in its clinical research efforts. Recently, the company announced the successful completion of the Phase 1a dose escalation clinical trial for its lead therapeutic candidate, TTX-MC138, which targets metastatic cancer.

The trial's primary goal was to assess safety, and results showed excellent tolerability among participants, with no dose-limiting toxicities reported. TTX-MC138 is an innovative therapeutic designed to inhibit microRNA-10b, a crucial factor in cancer metastasis. The early results indicate not just safety but also disease stabilization, marking a promising step forward for advanced cancer treatments.

The Phase 1a trial involved 16 patients who received a total of 86 doses of TTX-MC138. On average, participants remained on treatment for approximately 11.3 weeks, with some patients continuing treatment for up to 52.4 weeks, demonstrating a significant commitment to the trial. Importantly, three patients remain enrolled and are actively receiving treatment, showcasing the potential for long-term disease management through TTX-MC138.

Among the findings, an impressive 64% of evaluable patients achieved stable disease—where patients experienced no worsening of their cancer—for at least six months. This statistic gives hope that TTX-MC138 may provide effective cancer control for those suffering from debilitating metastatic tumors.

Dr. Keith Flaherty, the Director of Clinical Research at the Massachusetts General Hospital Cancer Center and a member of TransCode’s advisory board, praised the trial's results. He highlighted the need for safe and tolerable therapies in patients with advanced cancer, stating that the trial's findings provide a solid foundation for advancing the clinical development of TTX-MC138.

Further supporting these positive outcomes, the pharmacokinetics profile indicated that TTX-MC138 achieved drug bioavailability consistent with earlier preclinical studies. Notably, one patient with metastatic thyroid cancer exhibited remarkable progress, with decreased thyroglobulin levels, a known tumor marker, suggesting a positive response to the treatment over the past year.

As a result of these promising findings, TransCode plans to initiate Phase 2a clinical trials aimed at evaluating the efficacy of TTX-MC138 in patients with circulating tumor DNA (ctDNA) positive colorectal cancer. This advancement may open up new therapeutic avenues for patients who have undergone previous treatment but are at high risk for cancer recurrence.

In terms of future outlook, TransCode remains optimistic about TTX-MC138's potential to offer a breakthrough therapeutic option for patients with limited treatment alternatives. The ongoing study will further explore the drug's impact on disease progression and patient outcomes, aligning with the company's commitment to providing innovative solutions for challenging cancers.

TransCode Therapeutics is committed to developing cutting-edge therapies that address the growing need for effective metastatic cancer treatment options. The Phase 1a trial's successes afford hope to patients and advance the company’s position as a forward-thinker in cancer therapeutics.

For more details on the trial, please visit clinicaltrials.gov (NCT Identifier NCT06260774)